CoChat

Islet cell hyperexpression of HLA class I antigens: a defining feature in type 1 diabetes

Open access

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index; none of the 34 sources its claims cite is checked for support yet.

Abstract

AIMS/HYPOTHESIS: Human pancreatic beta cells may be complicit in their own demise in type 1 diabetes, but how this occurs remains unclear. One potentially contributing factor is hyperexpression of HLA class I antigens. This was first described approximately 30 years ago, but has never been fully characterised and was recently challenged as artefactual. Therefore, we investigated HLA class I expression at the protein and RNA levels in pancreases from three cohorts of patients with type 1 diabetes. The principal aims were to consider whether HLA class I hyperexpression is artefactual and, if not, to determine the factors driving it. METHODS: Pancreas samples from type 1 diabetes patients with residual insulin-containing islets (n = 26) from the Network for Pancreatic Organ donors with Diabetes (nPOD), Diabetes Virus Detection study (DiViD) and UK recent-onset type 1 diabetes collections were immunostained for HLA class I isoforms, signal transducer and activator of transcription 1 (STAT1), NLR family CARD domain containing 5 (NLRC5) and islet hormones. RNA was extracted from islets isolated by laser-capture microdissection from nPOD and DiViD samples and analysed using gene-expression arrays. RESULTS: Hyperexpression of HLA class I was observed in the insulin-containing islets of type 1 diabetes patients from all three tissue collections, and was confirmed at both the RNA and protein levels. The expression of β2-microglobulin (a second component required for the generation of functional HLA class I complexes) was also elevated. Both 'classical' HLA class I isoforms (i.e. HLA-ABC) as well as a 'non-classical' HLA molecule, HLA-F, were hyperexpressed in insulin-containing islets. This hyperexpression did not correlate with detectable upregulation of the transcriptional regulator NLRC5. However, it was strongly associated with increased STAT1 expression in all three cohorts. Islet hyperexpression of HLA class I molecules occurred in the insulin-containing islets of patients with recent-onset type 1 diabetes and was also detectable in many patients with disease duration of up to 11 years, declining thereafter. CONCLUSIONS/INTERPRETATION: Islet cell HLA class I hyperexpression is not an artefact, but is a hallmark in the immunopathogenesis of type 1 diabetes. The response is closely associated with elevated expression of STAT1 and, together, these occur uniquely in patients with type 1 diabetes, thereby contributing to their selective susceptibility to autoimmune-mediated destruction.

Overview

CoChat Summary

TL;DR

This study reports that islet-cell HLA class I hyperexpression is real, reproducible across three type 1 diabetes pancreas cohorts, and present at both protein and RNA levels. The hyperexpression is associated with elevated STAT1, not NLRC5, and is strongest in insulin-containing islets near diagnosis, then declines with disease duration.

Key findings

  • HLA class I hyperexpression was observed in insulin-containing islets from all three cohorts and was not seen in controls; it was restricted mainly to insulin-containing islets, while insulin-deficient islets showed normal expression.
  • In laser-captured islets, RNA levels were elevated for HLA-A (1.9 ± 0.14-fold), HLA-B (2.15 ± 0.16-fold), HLA-C (2.02 ± 0.09-fold), and β2-microglobulin (2.07-fold) in the DiViD cohort; nPOD showed similar but less marked trends.
  • A non-classical HLA molecule, HLA-F, was also upregulated, by 1.71 ± 0.04-fold at the RNA level in DiViD and confirmed at the protein level.
  • STAT1 correlated positively with HLA-ABC expression, with Spearman’s r = 0.5454, p < 0.0001; by contrast, NLRC5 did not correlate with HLA-ABC hyperexpression (p = 0.4504).
  • HLA-ABC hyperexpression was seen in patients with disease duration up to 11 years and then declined; the proportion of insulin-containing islets hyperexpressing HLA-ABC decreased with duration (r = –0.883, p < 0.0001).

Methods

  • Pancreas tissue from 26 type 1 diabetes patients with residual insulin-containing islets and 17 control individuals was analyzed across three cohorts: nPOD, DiViD, and a UK collection.
  • FFPE and frozen sections were stained for HLA class I isoforms, STAT1, NLRC5, β2-microglobulin, and islet hormones; islets from nPOD and DiViD were also laser-capture microdissected for RNA extraction.
  • Gene-expression arrays were used for RNA analysis, and statistical testing used t tests or Satterthwaite corrected two-sample tests, with p < 0.05 as the significance threshold.

Limitations

  • The paper states that the disease process in living patients cannot be studied non-invasively, so conclusions rely on tissue recovered after death or by pancreas biopsy.
  • The authors note that HLA-I hyperexpression had previously been studied in relatively few patients, and that earlier RNA studies were limited; this paper addresses that by using more cohorts and samples.
  • Evident from the text: the RNA analyses were performed on pooled, laser-captured islets that did not distinguish hyperexpressing from normal islets, or insulin-containing from insulin-deficient islets at collection, which limits cell-level specificity of the transcript data.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1007/s00125-016-4067-4

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Immunocytochemical analysis of the expression HLA-ABC in pancreas tissue. (a) Pancreas sections from two individuals with recent-onset type 1 diabetes from the DiViD cohort showing insulin and HLA-ABC immunostaining on serial sections. ICIs are indicated with red asterisks (magnification ×40 for the whole tissue section and ×100 for the islet). (b) Immunofluorescence analysis of HLA-ABC expression in frozen pancreas from a patient with recent-onset type 1 diabetes from the nPOD cohort. Hyperexpression of HLA-ABC (red) was predominantly seen only in ICIs (green; inset) (magnification ×40 for the whole tissue section and ×400 for the islet)
Fig. 1 Immunocytochemical analysis of the expression HLA-ABC in pancreas tissue. (a) Pancreas sections from two individuals with recent-onset type 1 diabetes from the DiViD cohort showing insulin and HLA-ABC immunostaining on serial sections. ICIs are indicated with red asterisks (magnification ×40 for the whole tissue section and ×100 for the islet). (b) Immunofluorescence analysis of HLA-ABC expression in frozen pancreas from a patient with recent-onset type 1 diabetes from the nPOD cohort. Hyperexpression of HLA-ABC (red) was predominantly seen only in ICIs (green; inset) (magnification ×40 for the whole tissue section and ×400 for the islet)CC BY · PubMed Central
Fig. 2 Correlation between HLA-ABC, β2M and insulin expression in controls and individuals with type 1 diabetes. (a) Analysis of β2M (green), HLA-ABC (red) and insulin (light blue) in an ICI from a non-diabetic control individual and a type 1 diabetes patient, and an IDI from the same individual. Scale bar, 25 μm. (b) The MFI of islet HLA-ABC expression was measured in 5–14 islets among non-diabetic control individuals (n = 4) and in the ICI and IDIs of nine individuals with type 1 diabetes (T1D) (five from the DiViD cohort, three from the UK cohort and one from the nPOD cohort). (c) The MFI of islet β2M expression was measured in 15 ICIs and 15 IDIs from each of three type 1 diabetes patients (two from the UK cohort and one from the nPOD cohort). This was compared with the expression in 20 islets from each of four non-diabetic control individuals (three from the UK cohort and one from the nPOD cohort). *p < 0.001
Fig. 2 Correlation between HLA-ABC, β2M and insulin expression in controls and individuals with type 1 diabetes. (a) Analysis of β2M (green), HLA-ABC (red) and insulin (light blue) in an ICI from a non-diabetic control individual and a type 1 diabetes patient, and an IDI from the same individual. Scale bar, 25 μm. (b) The MFI of islet HLA-ABC expression was measured in 5–14 islets among non-diabetic control individuals (n = 4) and in the ICI and IDIs of nine individuals with type 1 diabetes (T1D) (five from the DiViD cohort, three from the UK cohort and one from the nPOD cohort). (c) The MFI of islet β2M expression was measured in 15 ICIs and 15 IDIs from each of three type 1 diabetes patients (two from the UK cohort and one from the nPOD cohort). This was compared with the expression in 20 islets from each of four non-diabetic control individuals (three from the UK cohort and one from the nPOD cohort). *p < 0.001CC BY · PubMed Central
Fig. 3 Heat map illustrating the relative expression of HLA-ABC and B2M genes in control individuals and those with type 1 diabetes (T1D). The expression of each probe set is displayed separately in islets of: (a) seven nPOD non-diabetic controls age-matched to five DiViD patients; and (b) eight nPOD non-diabetic controls and nine nPOD type 1 diabetic donors. Expression values are shown in arbitrary units and the heat map illustrates relative expression ranging from low (green) to high (red). In (b), a comparison with the level of expression scored after immunohistochemical analysis of islets present in nearby pancreatic blocks from the same patients is provided (black, hyperexpression; blue, elevated expression; grey, normal expression), together with an indication of the extent of insulin immunopositivity
Fig. 3 Heat map illustrating the relative expression of HLA-ABC and B2M genes in control individuals and those with type 1 diabetes (T1D). The expression of each probe set is displayed separately in islets of: (a) seven nPOD non-diabetic controls age-matched to five DiViD patients; and (b) eight nPOD non-diabetic controls and nine nPOD type 1 diabetic donors. Expression values are shown in arbitrary units and the heat map illustrates relative expression ranging from low (green) to high (red). In (b), a comparison with the level of expression scored after immunohistochemical analysis of islets present in nearby pancreatic blocks from the same patients is provided (black, hyperexpression; blue, elevated expression; grey, normal expression), together with an indication of the extent of insulin immunopositivityCC BY · PubMed Central
Fig. 4 Expression of HLA-F in control individuals and type 1 diabetes patients. (a) Heat map illustrating the relative expression of the HLA-F probe sets in seven nPOD non-diabetic controls age-matched to five DiViD patients. (b) Representative immunostaining of islets from an individual without diabetes and a patient with type 1 diabetes with anti-HLA-F. (c) Immunofluorescence staining of HLA-F (green), insulin (light blue) and glucagon (red) in an ICI (white arrowheads) and an IDI (orange arrowheads) of a DiViD type 1 diabetes patient, and an islet from an nPOD control donor. Scale bar, 25 μm
Fig. 4 Expression of HLA-F in control individuals and type 1 diabetes patients. (a) Heat map illustrating the relative expression of the HLA-F probe sets in seven nPOD non-diabetic controls age-matched to five DiViD patients. (b) Representative immunostaining of islets from an individual without diabetes and a patient with type 1 diabetes with anti-HLA-F. (c) Immunofluorescence staining of HLA-F (green), insulin (light blue) and glucagon (red) in an ICI (white arrowheads) and an IDI (orange arrowheads) of a DiViD type 1 diabetes patient, and an islet from an nPOD control donor. Scale bar, 25 μmCC BY · PubMed Central
Fig. 5 Expression of NLRC5 in the islets of control individuals and those with type 1 diabetes. (a) Representative islets from an individual without diabetes and a patient with type 1 diabetes are shown (red, HLA-ABC; green, NLRC5; light blue, insulin; dark blue, DAPI). Scale bar, 25 μm. (b) MFI values for NLRC5 protein expression were quantified after immunostaining in five islets per section from four control and four type 1 diabetes (three from the UK, one from nPOD) samples (p = 0.0704). (c) Expression of NLRC5 was compared in RNA isolated from islets of individuals with and without type 1 diabetes (p = 0.4504)
Fig. 5 Expression of NLRC5 in the islets of control individuals and those with type 1 diabetes. (a) Representative islets from an individual without diabetes and a patient with type 1 diabetes are shown (red, HLA-ABC; green, NLRC5; light blue, insulin; dark blue, DAPI). Scale bar, 25 μm. (b) MFI values for NLRC5 protein expression were quantified after immunostaining in five islets per section from four control and four type 1 diabetes (three from the UK, one from nPOD) samples (p = 0.0704). (c) Expression of NLRC5 was compared in RNA isolated from islets of individuals with and without type 1 diabetes (p = 0.4504)CC BY · PubMed Central
Fig. 6 Expression of STAT1 and HLA-ABC in islets from control individuals and those with type 1 diabetes. (a) Representative islets from a control individual and from a type 1 diabetes patient were immunostained for STAT1 (green), HLA-ABC (red), insulin (light blue) and DAPI (dark blue). The localisation of STAT1 is shown in beta cells (white arrowheads) and non-beta cells (orange arrowheads). Scale bar, 25 μm. (b) MFI values for STAT1 and HLA-ABC expression were quantified and correlated from a minimum of seven ICIs in seven patients with type 1 diabetes (T1D) among the DiViD and UK (E560) cohorts (Spearman’s rank coefficient =0.5454, p < 0.0001). (c) Correlation between the expression of STAT1 mRNA and disease duration in nPOD type 1 diabetes patients with residual ICIs (p < 0.05). (d) Analysis of STAT1 expression in RNA isolated from islets from DiViD patients and age-matched control donors (nPOD) (p = 0.0263)
Fig. 6 Expression of STAT1 and HLA-ABC in islets from control individuals and those with type 1 diabetes. (a) Representative islets from a control individual and from a type 1 diabetes patient were immunostained for STAT1 (green), HLA-ABC (red), insulin (light blue) and DAPI (dark blue). The localisation of STAT1 is shown in beta cells (white arrowheads) and non-beta cells (orange arrowheads). Scale bar, 25 μm. (b) MFI values for STAT1 and HLA-ABC expression were quantified and correlated from a minimum of seven ICIs in seven patients with type 1 diabetes (T1D) among the DiViD and UK (E560) cohorts (Spearman’s rank coefficient =0.5454, p < 0.0001). (c) Correlation between the expression of STAT1 mRNA and disease duration in nPOD type 1 diabetes patients with residual ICIs (p < 0.05). (d) Analysis of STAT1 expression in RNA isolated from islets from DiViD patients and age-matched control donors (nPOD) (p = 0.0263)CC BY · PubMed Central

Verification

Claims the paper makes

0 Valid · 0 Not valid · 16 Not checked · 36 Own results and interpretations

23 more claims

Create a free account to see all 52 claims and to verify the 34 references still open.

See all claims — free account
  • It may state two separate claims as one. 17
  • Probably not a substantial claim. 8

Create a free account to see these claims.

Citations

Cites

Show all 43 references

Cited by

See all 300

Metadata

Authors
Richardson, S. J., Rodriguez-Calvo, T., Gerling, I. C., Mathews, C. E., Kaddis, J. S., Russell, M. A., Zeissler, M., Leete, P., Krogvold, L., Dahl-Jørgensen, K., von Herrath, M., Pugliese, A., Atkinson, M. A., & Morgan, N. G.
Affiliations
  • University of Exeter (GB)
  • University of Tennessee Health Science Center (US)
  • University of Florida Health (US)
  • City Of Hope National Medical Center (US)
  • Oslo University Hospital (NO)
  • University of Miami (US)
Corresponding author
  • Richardson, Sarah J.
  • Morgan, Noel G.
Venue
Diabetologia
Published
2016-08-09
Volume
59
Issue
11
Pages
2448-2458
ISSN
  • 0012-186X (ISSN-L)
  • 1432-0428
OpenAlex
W2513957711
Cited by
298
References
43
Citations by year
2026: 26 · 2025: 39 · 2024: 30 · 2023: 23 · 2022: 36 · 2021: 37 · 2020: 28 · 2019: 33 · 2018: 25 · 2017: 19 · 2016: 2
FWCI
21.27
Type
journal article
Language
en
Open access
Licence
Locations
  • Diabetologia (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Open Research Exeter (University of Exeter) (acceptedVersion)
  • Figshare (submittedVersion)
  • Royal Devon and Exeter Research Repository (Royal Devon and Exeter) (submittedVersion)
Funders
  • Seventh Framework Programme (261441)
  • Diabetes Research & Wellness Foundation
  • National Institutes of Health (UC4 DK104155)
  • JDRF (JDRF 25-2012-516)
  • South-Eastern Norway Regional Health Authority
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Endoplasmic Reticulum Stress and Disease
Keywords
type 1 diabetes, pancreatic beta cells, islets, STAT1, NLRC5, HLA-F, beta2-microglobulin, islet autoimmunity, immunopathogenesis, recent-onset type 1 diabetes, disease duration, islet gene expression, HLA-ABC
MeSH terms
Diabetes Mellitus, Type 1, Female, Fluorescent Antibody Technique, Humans, Immunohistochemistry, Insulin, Islets of Langerhans, Male, Pancreas, Histocompatibility Antigens Class I, STAT1 Transcription Factor, In Vitro Techniques

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Islet cell hyperexpression of HLA class I antigens: a defining feature in type 1 diabetes. https://app.cochat.ai/papers/10.1007/s00125-016-4067-4
The paper
Richardson, S. J., Rodriguez-Calvo, T., Gerling, I. C., Mathews, C. E., Kaddis, J. S., Russell, M. A., Zeissler, M., Leete, P., Krogvold, L., Dahl-Jørgensen, K., von Herrath, M., Pugliese, A., Atkinson, M. A., & Morgan, N. G. (2016). Islet cell hyperexpression of HLA class I antigens: a defining feature in type 1 diabetes. Diabetologia. https://doi.org/10.1007/s00125-016-4067-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.